← All compounds
Well Researched

Cerebrolysin

Neuropeptide Preparation | Neurological Recovery

Cerebrolysin is a standardized neuropeptide preparation derived from purified porcine brain proteins, containing bioactive peptides and amino acids that exhibit neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement.

Daily dose

10-50 mL

Frequency

Once daily

Cycle length

7-30 days

Storage

Room temp ≤25°C

Key benefits

Direct brain delivery, standardized dosing, extensive clinical evidence, ready-to-use formulation

How it works

IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors

Dosage protocols

Goal

Small Volume IV

Dose

Up to 10 mL · Once daily

Route

Undiluted IV slow push over 3 minutes

Goal

Intramuscular (Lower Doses)

Dose

Up to 5 mL · Once daily

Route

Undiluted IM injection over 3 minutes

Goal

Acute Stroke

Dose

20-50 mL · Once daily for 10-21 days

Route

IV infusion (diluted to 100mL minimum)

Goal

Traumatic Brain Injury

Dose

20-50 mL · Once daily for 7-30 days

Route

IV infusion (diluted to 100mL minimum)

Goal

Alzheimer's Disease

Dose

10-30 mL · 5 days weekly for 4 weeks

Route

IV injection/infusion (2-4 cycles yearly)

Goal

Vascular Dementia

Dose

10-30 mL · 5 days weekly for 4 weeks

Route

IV injection/infusion (2-4 cycles yearly)

Research indications

cognitive

Alzheimer's Disease - Mixed Evidence — Meta-analyses show modest cognitive improvements, though clinical significance remains debated in medical literature
Vascular Dementia - Established Efficacy — Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements with well-documented protocols
Post-Stroke Cognitive Recovery — Large meta-analysis shows significant NIHSS improvements, though other studies found no functional benefit

neuroprotection

Acute Stroke - Evidence Mixed — Largest meta-analysis (1,879 patients) shows NIHSS benefits, but independent analysis found no mRS/BI improvement
Traumatic Brain Injury - Strong Evidence — Multiple trials including CAPTAIN series and large systematic review confirm GCS/GOS improvements
Subarachnoid Hemorrhage - Emerging Evidence — Pilot trial shows promising 6-month outcomes, but requires larger confirmatory studies

recovery

Motor Function Recovery - Variable Results — Some studies show enhanced motor recovery, but results vary significantly between trials
Neurological Function - Time-Dependent — Early administration within 72 hours shows better outcomes than delayed treatment
Functional Independence - Limited Evidence — Some improvement in disability scales, though long-term functional benefits remain unclear

Administration

injectable

Interactions

Compatible
Piracetam — Safe combination demonstrated in clinical studies with no significant interactions. Both compounds work through different mechanisms to support cognitive function.
Compatible
Donepezil — No significant interactions reported. May have synergistic cognitive effects when used together in Alzheimer's treatment protocols.
Monitor Combination
SSRIs — Potential additive neurotropic effects. Monitor for enhanced antidepressant effects and consider dose adjustment if combining long-term.
Use Caution
Tricyclic Antidepressants — May have additive neurological effects. Requires careful monitoring and potential dose adjustments of antidepressant medications.
Avoid Combination
Amino Acid Solutions — Contraindicated per official prescribing information. Cerebrolysin should not be mixed with balanced amino acid solutions in same infusion.
Avoid Combination
Cardiovascular Medications — Official prescribing information states Cerebrolysin should not be mixed with cardiovascular medicinal products in same infusion.
Avoid Combination
Vitamin Solutions — Per official guidelines, Cerebrolysin should not be mixed with vitamin solutions in same IV infusion due to compatibility issues.
Monitor Combination
Noopept — Both enhance BDNF and affect glutamatergic signaling. Cerebrolysin contains neurotrophic peptides, Noopept modulates AMPA/NMDA receptors. Potential for additive cognitive effects - start with lower doses when combining and monitor for overstimulation.

Safety notes

Monitor for allergic reactions during first administration - generally well tolerated

Contraindicated in epilepsy and severe renal insufficiency per official prescribing information

Clinical evidence shows mixed results - some large studies positive, others neutral

Research integrity concerns have been raised about some published studies

Not approved in USA but used clinically in over 50 countries worldwide

Use disposable one-way infusion sets to guarantee sterility

Research studies

TBI Systematic Review - Positive Outcomes (2023)

Humans | 10-50 mL daily | Variable duration | GCS/GOS improvements

Analysis of 8,749 TBI patients across 10 studies confirms statistically significant improvements in neurological scores

View study →

CAPTAIN II Trial - Traumatic Brain Injury (2020)

Humans | 30-50 mL daily | 10-28 days | Significant neurological improvement

Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores

View study →

Subarachnoid Hemorrhage Pilot Trial (2020)

Humans | 30 mL daily | 14 days | Improved 6-month outcomes

First randomized trial in SAH patients showing promising results with 76% vs 48% favorable outcomes

View study →

Nine-Trial Stroke Meta-Analysis - Positive Results (2017)

Humans | 30-50 mL daily | 10-21 days | NIHSS improvement, NNT=7.7

Largest positive meta-analysis showing significant neurological improvements in 1,879 stroke patients

View study →

Conflicting Stroke Meta-Analysis - Neutral Results (2017)

Humans | Various doses | 72-hour window | No significant mRS/BI improvement

Independent meta-analysis of 1,779 patients found no significant benefits in functional outcomes, highlighting mixed evidence

View study →

Alzheimer's Disease Meta-Analysis - Mixed Evidence

Humans | 30 mL daily | 4 weeks | Modest cognitive improvements

Meta-analysis shows small but significant improvements in some cognitive measures, though clinical relevance debated

View study →

Related compounds

SemaxNA Semax AmidateDihexaP21